Physician profile
Ritch Go
NPI 1255843744
$6,230.54
in general payments reported to CMS, 2019-2025
33 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $998 · 2022: $688 · 2023: $820 · 2024: $2,087 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $688.59 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $667.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $652.33 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $452.29 | 2021-2025 | |
| Abbott Laboratories | $435.70 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $301.98 | 2022-2025 | |
| Astellas Pharma US INC | $284.67 | 2021-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.99 | 2021-2025 | Jardiance |
| Abbvie INC. | $243.03 | 2021-2025 | |
| Exact Sciences Corporation | $225.45 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $207.98 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $205.06 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $188.39 | 2021-2024 | Xarelto |
| Amgen INC. | $177.05 | 2021-2025 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $174.31 | 2021-2024 | Verquvo, Belsomra, Steglatro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $126.21 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $113.65 | 2021-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $112.77 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $102.18 | 2021-2025 | |
| Almatica Pharma LLC | $89.91 | 2024 | Loreev Xr, Teriparatide |
| Corcept Therapeutics | $85.06 | 2024 | Korlym |
| Horizon Therapeutics Plc | $69.75 | 2021-2023 | Krystexxa |
| Gilead Sciences, INC. | $65.56 | 2023-2024 | Vemlidy, Epclusa |
| Phathom Pharmaceuticals, INC. | $59.13 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $44.80 | 2021 | |
| Lifescan, INC. | $43.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.91 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $31.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.99 | 2025 | Rexulti |
| Lundbeck LLC | $16.45 | 2023 | Rexulti |
| Inogen, INC. | $15.81 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Optinose US, INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritch Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.